000 | 01951 a2200529 4500 | ||
---|---|---|---|
005 | 20250513223121.0 | ||
264 | 0 | _c20001207 | |
008 | 200012s 0 0 eng d | ||
022 | _a0167-5273 | ||
024 | 7 |
_a10.1016/s0167-5273(00)00282-5 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aQasim, A | |
245 | 0 | 0 |
_aFailed thrombolysis in myocardial infarction. _h[electronic resource] |
260 |
_bInternational journal of cardiology _cAug 2000 |
||
300 |
_a5-14 p. _bdigital |
||
500 | _aPublication Type: Comparative Study; Journal Article; Review | ||
650 | 0 | 4 | _aAbciximab |
650 | 0 | 4 | _aAngioplasty, Balloon, Coronary |
650 | 0 | 4 |
_aAntibodies, Monoclonal _xtherapeutic use |
650 | 0 | 4 |
_aAnticoagulants _xtherapeutic use |
650 | 0 | 4 |
_aAntithrombins _xtherapeutic use |
650 | 0 | 4 |
_aAspirin _xtherapeutic use |
650 | 0 | 4 | _aClinical Trials as Topic |
650 | 0 | 4 | _aElectrocardiography |
650 | 0 | 4 |
_aFibrinolytic Agents _ximmunology |
650 | 0 | 4 | _aHirudin Therapy |
650 | 0 | 4 |
_aHirudins _xanalogs & derivatives |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aImmunoglobulin Fab Fragments _xtherapeutic use |
650 | 0 | 4 | _aMonitoring, Physiologic |
650 | 0 | 4 |
_aMyocardial Infarction _xdrug therapy |
650 | 0 | 4 |
_aPeptide Fragments _xtherapeutic use |
650 | 0 | 4 |
_aPlasminogen Activators _ximmunology |
650 | 0 | 4 |
_aPlatelet Aggregation Inhibitors _xtherapeutic use |
650 | 0 | 4 |
_aPlatelet Glycoprotein GPIIb-IIIa Complex _xantagonists & inhibitors |
650 | 0 | 4 | _aPrognosis |
650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
650 | 0 | 4 |
_aRecombinant Proteins _xtherapeutic use |
650 | 0 | 4 | _aRecurrence |
650 | 0 | 4 |
_aStreptokinase _ximmunology |
650 | 0 | 4 | _aThrombolytic Therapy |
650 | 0 | 4 | _aTime Factors |
700 | 1 | _aChauhan, A | |
700 | 1 | _aMore, R S | |
773 | 0 |
_tInternational journal of cardiology _gvol. 75 _gno. 1 _gp. 5-14 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0167-5273(00)00282-5 _zAvailable from publisher's website |
999 |
_c10997254 _d10997254 |